Using existing NHS datasets to determine outcomes of cancer medicines : a feasibility study

Baillie, Kelly and Mueller, Tanja and Pan, Jiafeng and Crearie, Christine and Laskey, Jennifer and Jones, Robert and Bennie, Marion (2018) Using existing NHS datasets to determine outcomes of cancer medicines : a feasibility study. In: 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, 2018-08-22 - 2018-08-26, The Prague Congress Centre. (In Press)

[img]
Preview
Text (Baillie-etal-ICPTRM-2018-Using-existing-NHS-datasets-to-determine-outcomes-of-cancer-medicines)
Baillie_etal_ICPTRM_2018_Using_existing_NHS_datasets_to_determine_outcomes_of_cancer_medicines.pdf
Accepted Author Manuscript

Download (522kB)| Preview

    Abstract

    Based on recent clinical trial evidence, updated treatment guidelines in the UK recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of cardiovascular disease. However, with this high statin dose, there are concerns about a potential increase in the incidence of statin-related side effects, which might affect patients’ adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of statin intensity on adherence and persistence to therapy.